thymosin-beta(4) and diquafosol

thymosin-beta(4) has been researched along with diquafosol* in 1 studies

Other Studies

1 other study(ies) available for thymosin-beta(4) and diquafosol

Article	Year
RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model. Scientific reports, 2018, Jul-12, Volume: 8, Issue:1 This study evaluated the clinical activity of RGN-259 (thymosin β4) in comparison with cyclosporine A (CsA), diquafosol (DQS), and lifitegrast (LFA) in a murine model of dry eye. The model was NOD.B10-H2 Topics: Animals; Conjunctiva; Cornea; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Female; Goblet Cells; Humans; Inflammation Mediators; Lacrimal Apparatus; Male; Mice; Mice, Inbred NOD; Mucins; Ophthalmic Solutions; Phenylalanine; Polyphosphates; Prescription Drugs; Scopolamine; Sulfones; Tears; Thymosin; Treatment Outcome; Uracil Nucleotides	2018

Article

Year

RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.

Scientific reports, 2018, Jul-12, Volume: 8, Issue:1

This study evaluated the clinical activity of RGN-259 (thymosin β4) in comparison with cyclosporine A (CsA), diquafosol (DQS), and lifitegrast (LFA) in a murine model of dry eye. The model was NOD.B10-H2

Topics: Animals; Conjunctiva; Cornea; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Female; Goblet Cells; Humans; Inflammation Mediators; Lacrimal Apparatus; Male; Mice; Mice, Inbred NOD; Mucins; Ophthalmic Solutions; Phenylalanine; Polyphosphates; Prescription Drugs; Scopolamine; Sulfones; Tears; Thymosin; Treatment Outcome; Uracil Nucleotides

2018